What is an antibody drug conjugate? Antibody-drug conjugates (ADCs) bridged by smart linkers have an improved therapeutic window that efficiently targets tumor cells and tissues. ADCs comprise a high affinity antibody and a cytotoxic payload coupled by a suitable linker. The development of protein engineering, linker chemistry and new cytotoxic loads presupposes ADC to be a safe and effective anticancer therapy for personalized medicine. ADC has become a more powerful tool for targeting cancer treatment, and its "drug antibody ratio" (DAR) has also improved, and the number of clinical trials has also increased significantly.
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm